Product image of Mepivacaina Ogna (Mepivacaine Hydrochloride) supplied by GNH India

Mepivacaina Ogna

Active Ingredient:
Mepivacaine Hydrochloride
Origin:
EU

Mepivacaina Ogna (Mepivacaine Hydrochloride)

Mepivacaine Hydrochloride, the active ingredient in Mepivacaina Ogna, is a local anesthetic presented as a sterile solution for dental use. It produces a reversible loss of sensation by blocking nerve impulse transmission, facilitating painless dental procedures such as extractions, restorations, and periodontal surgery in adult patients.

GNH India supplies Mepivacaina Ogna as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, emphasizing quality assurance, regulatory compliance, and timely delivery across EU and other markets through a robust logistics platform.

Manufacturer / TM Owner

Giovanni Ogna E Figli S.R.L.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Mepivacaina Ogna, a local anesthetic, provides targeted numbness for dental tissues during various procedures.
  • Tooth extraction: enables painless removal of teeth by delivering rapid‑onset anesthesia to the periodontal ligament and surrounding bone.
  • Restorative dentistry (fillings, crowns, bridges): creates a comfortable field for precise work on dentin and enamel without patient discomfort.
  • Periodontal surgery: provides adequate anesthesia for gum flap elevation, scaling, and root planing, facilitating effective surgical outcomes.
  • Root canal therapy: ensures analgesia of the pulp chamber and root canals during endodontic treatment.

How It Works

  • Mepivacaine Hydrochloride blocks voltage‑gated sodium channels on neuronal membranes, preventing the influx of sodium ions required for depolarisation. This inhibition halts the generation and propagation of nerve impulses, resulting in a reversible loss of sensation in the area where the drug is administered.

Side Effects

Mepivacaina Ogna may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

  • Tingling or numbness at the injection site
  • Mild headache
  • Dizziness or light‑headedness
  • Transient swelling or bruising
  • Nausea
  • Temporary metallic taste

Serious or Rare Side Effects

  • Cardiovascular toxicity (arrhythmias, hypotension)
  • Central nervous system toxicity (seizures, loss of consciousness)
  • Allergic reactions (rash, urticaria, anaphylaxis)
  • Methemoglobinemia
  • Persistent paresthesia
  • Severe tissue necrosis at injection site

Precautions & Warnings

  • Before using Mepivacaina Ogna, clinicians should consider several safety measures.
  • Allergy assessment: verify that the patient has no known hypersensitivity to amide‑type local anesthetics.
  • Cardiovascular monitoring: observe patients with pre‑existing heart disease for arrhythmias or blood‑pressure changes.
  • Dosage limit: avoid exceeding the maximum recommended total dose for the procedure.
  • Pregnancy consideration: use only when the benefit outweighs potential risk, as safety data are limited.
  • Drug interactions: review concomitant medications that may affect cardiac conduction or metabolism.
  • Store below 25°C: keep in the original container, protect from moisture and light.

Avoid Interactions

Mepivacaina Ogna can interact with other agents that influence cardiac or nervous system function.

Major Interactions (Avoid)

  • Class I antiarrhythmics (e.g., quinidine, procainamide): may increase cardiotoxicity.
  • Beta‑blockers: can potentiate bradycardia and hypotension.

Moderate Interactions (Monitor Closely)

  • MAO inhibitors and tricyclic antidepressants: may affect cardiac conduction.
  • Ephedrine or phenylephrine: may alter the vasoconstrictive effect of adjunctive agents.
  • Concurrent use of other local anesthetics: risk of cumulative systemic toxicity.

Frequently Asked Questions

Mepivacaina Ogna is a dental local anesthetic used to provide reversible numbness during procedures such as tooth extractions, restorative work, periodontal surgery, and endodontic treatment. It allows clinicians to perform invasive dental work without causing pain to the patient.

Mepivacaine Hydrochloride blocks voltage‑gated sodium channels on nerve membranes, preventing sodium influx that is essential for depolarisation. By inhibiting nerve impulse generation and propagation, it produces a temporary loss of sensation in the targeted area.

The appropriate dose of Mepivacaina Ogna is determined by the prescribing dental professional based on the specific procedure, patient weight, and overall health. Clinicians calculate the dose to stay within recommended safety limits for each individual case.

Safety data for Mepivacaina Ogna during pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by the treating clinician in consultation with the patient.

To order Mepivacaina Ogna, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both Mepivacaina Ogna and lidocaine are amide‑type local anesthetics used in dentistry. Mepivacaine typically has a slightly longer duration of action and less vasodilatory effect, which can reduce the need for added vasoconstrictors. Choice between them depends on the clinical situation and practitioner preference.

Mepivacaina Ogna should be stored below 25 °C in its original packaging, protected from moisture and direct light. Keeping the product at controlled room temperature helps maintain its potency and sterility until the expiry date.

Mepivacaina Ogna is administered by a qualified dental professional as a local injection into the soft tissues surrounding the tooth or surgical site. The solution is delivered using a sterile syringe and needle, allowing rapid onset of anesthesia in the targeted area.

Serious risks include systemic toxicity such as cardiovascular events (arrhythmias, hypotension), central nervous system effects (seizures, loss of consciousness), and rare allergic reactions that can progress to anaphylaxis. Prompt recognition and supportive care are essential if these events occur.

Patients with a known hypersensitivity to mepivacaine, other amide‑type local anesthetics, or any component of the formulation should avoid its use. It is also contraindicated in individuals with severe cardiac conduction disorders or uncontrolled epilepsy without careful medical supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mepivacaine Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT